独立董事：李卫锋、程增江、方芳 2025 年 8 月 8 日 一、审议通过《关于与关联方签署生产信息化系统相关协议暨关联交易的议 案》 经全体与会独立董事审议：本次关联交易是基于公司实施生产数字化智能管 理的实际业务而产生，主要目的是为了加快推进数字化、智能化在制药产业中融 合，实现药品生产数字化智能管理，符合公司和全体股东的利益，具有必要性。 本次交易严格按照公司采购管理制度及采购招标流程遴选供应商，按照公平、公 开、公正的原则从服务能力、解决方案、项目实施经验、项目团队能力等方面进 行综合全面考察，通过招投标流程比价，在符合商业惯例的前提下，从交易价格 谈判、付款方式及验收标准等方面保证上市公司利益，不会损害公司及股东特别 是中小股东的利益。我们同意将该关联交易事项提交公司第四届董事会第七次会 议审议，届时关联董事将回避表决。 表决结果：3 票同意、0 票反对、0 票弃权。 成都苑东生物制药股份有限公司 第四届独立董事专门会议第三次会议决议 成都苑东生物制药股份有限公司（以下称"公司"）第四届独立董事专门会议 第三次会议通知于2025年8月7日以电话/微信等方式临时向全体独立董事发出， 会议于 2025 ...

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 成都苑东生物制药股份有限公司（以下简称"公司"）第四届监事会第六次会 议于 2025 年 8 月 18 日在公司会议室以现场形式召开。会议通知已于 2025 年 8 月 8 日以电话通知、电子邮件等方式送达全体监事。本次会议应出席监事 3 名， 实际出席监事 3 名，本次会议由监事会主席罗雯婕女士主持，公司董事会秘书等 列席会议。本次会议的召集和召开程序符合有关法律、行政法规、部门规章、规 范性文件和《公司章程》的规定，会议决议合法、有效。 二、监事会会议审议情况 证券代码：688513 证券简称：苑东生物 公告编号：2025-058 成都苑东生物制药股份有限公司 第四届监事会第六次会议决议公告 表决结果：同意 3 票，反对 0 票，弃权 0 票。同意票占本次监事会有效表决 票数的 100%，全票表决通过。 经审议，会议以投票表决的方式通过以下议案： （一）审议通过《关于<公司 2025 年半年度报告及其摘要>的议案》 监事会认为：公司 2025 年半 ...

成都苑东生物制药股份有限公司 第四届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 证券代码：688513 证券简称：苑东生物 公告编号：2025-057 成都苑东生物制药股份有限公司（以下称"公司"）第四届董事会第七次会议 于 2025 年 8 月 18 日以现场和通讯相结合的方式召开。会议通知已于 2025 年 8 月 8 日以专人送达、电话通知、电子邮件等形式送达全体董事。本次会议由董事 长王颖女士主持，应出席董事 9 名，实际出席董事 9 名。本次会议的召集、召开 和表决程序符合《中华人民共和国公司法》等相关法律法规和《成都苑东生物制 药股份有限公司章程》的规定，会议形成的决议合法有效。 二、董事会会议审议情况 经与会董事审议，逐项表决，形成决议如下： （一）审议通过《关于<公司 2025 年半年度报告及其摘要>的议案》 董事会同意《关于<公司 2025 年半年度报告及其摘要>的议案》。 表决结果：9 票赞成，0 票反对，0 票弃权。同意票占本次董事会有效表决 票数 ...

公司代码：688513 公司简称：苑东生物 成都苑东生物制药股份有限公司 1 / 200 2025 年半年度报告 成都苑东生物制药股份有限公司2025 年半年度报告 成都苑东生物制药股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告中详细阐述公司在生产经营过程中可能面临的各种风险及应对措施，敬请查 阅第三节"管理层讨论与分析"之"四、风险因素"。敬请投资者予以关注，注意投资风险。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人王颖、主管会计工作负责人伯小芹及会计机构负责人（会计主管人员）伯小芹 声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的公司未来计划、发展战略等前瞻性陈述，不构成公司对投资 ...

Group 1 - The chemical pharmaceutical sector increased by 2.34% on August 13, with Shouyao Holdings leading the gains [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] - Notable gainers in the chemical pharmaceutical sector included Shouyao Holdings, which rose by 19.99% to a closing price of 55.94, and Weichip Bio, which increased by 14.39% to 41.18 [1] Group 2 - The chemical pharmaceutical sector saw a net inflow of 342 million yuan from main funds, while retail investors contributed a net inflow of 426 million yuan [2] - Major stocks with significant net inflows included Heng Rui Pharmaceutical with 55.1 million yuan and Fu Xing Pharmaceutical with 23.4 million yuan [3] - Conversely, stocks like ST Sailong and ST Suwu experienced notable net outflows of 4.97% and 3.70%, respectively [2]

Core Viewpoint - Hunan Kelun Pharmaceutical Co., Ltd. has had its application for the injection of tosilate omadacycline accepted, marking a significant step in the development of this antibiotic in China, where no generic versions have been approved yet [1][12]. Group 1: Product Overview - Tosilate omadacycline is a novel aminomethylcycline antibiotic belonging to the tetracycline family, primarily used for treating community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) [3]. - The global sales of omadacycline exceeded $200 million in 2022, indicating a strong market demand driven by the increasing antibiotic resistance crisis [4]. Group 2: Market Performance - Since its launch in 2021, the sales of injection tosilate omadacycline in China have surged, with a reported increase of 905% in 2023, surpassing 100 million yuan [6]. - The sales are projected to continue growing, with an expected increase of 85.26% in 2024, reaching approximately 223 million yuan [6][9]. Group 3: Regulatory and Competitive Landscape - Currently, there are no approved generic versions of tosilate omadacycline in China, although several companies, including Qilu Pharmaceutical and Sichuan Meida Kanghua Pharmaceutical, have submitted applications that are under review [12]. - The rapid approval process for omadacycline, taking only eight months from NDA submission to approval, reflects the benefits of China's innovative drug policies [10]. Group 4: Strategic Implications for Companies - Hunan Kelun's involvement in the first generic competition for tosilate omadacycline is expected to enhance its market presence in the anti-infection sector, which is critical given the rising demand for innovative antibiotics [18]. - The inclusion of omadacycline in the "Clinical Urgently Needed Overseas New Drug List" underscores its importance in addressing the urgent need for new antibiotics in China [10][16].

金融界消息 截至2025年8月8日收盘，苑东生物（688513）报收于59.5元，下跌0.93%，换手率1.85%， 成交量3.27万手，成交金额1.94亿元。 资金流向方面，今日主力资金净流出1877.20万元，占比成交额9.67%。其中，超大单净流出1164.09万 元、占成交额6.0%，大单净流出713.11万元、占成交额3.67%，中单净流出流出837.36万元、占成交额 4.31%，小单净流入2714.56万元、占成交额13.99%。 苑东生物最新一期业绩显示，截至2025一季报，公司营业总收入3.06亿元、同比减少2.97%，归属净利 润6059.04万元，同比减少19.22%，扣非净利润4646.87万元，同比减少10.79%，流动比率3.365、速动比 率3.005、资产负债率20.17%。 天眼查商业履历信息显示，成都苑东生物制药股份有限公司，成立于2009年，位于成都市，是一家以从 事医药制造业为主的企业。企业注册资本17653.2256万人民币，实缴资本8650万人民币。公司法定代表 人为王颖。 通过天眼查大数据分析，成都苑东生物制药股份有限公司共对外投资了12家企业，参与招投标项目34 ...

Core Viewpoint - The article provides a ranking of open-end mutual funds based on their net asset value growth as of August 6, 2025, highlighting the top and bottom performers in the market [2][4][6]. Group 1: Top Performing Funds - The top 10 funds with the highest net value growth include: 1. Zhonghai Charm Yangtze River Delta Mixed Fund (3.1350) 2. Hengyue Smart Technology Mixed C Fund (1.1892) 3. Hengyue Smart Technology Mixed A Fund (1.1996) 4. Minsheng Jianyin Frontier Technology Mixed Fund (1.0201) 5. Tongtai Competitive Advantage Mixed A Fund (1.1032) 6. Tongtai Competitive Advantage Mixed C Fund (1.0802) 7. Furong Fuxin Mixed C Fund (2.1194) 8. Furong Fuxin Mixed A Fund (2.1560) 9. Hongyi Yuanfang Selected Mixed C Fund (1.1215) 10. Hongyi Yuanfang Selected Mixed A Fund (1.1231) [2][4]. Group 2: Bottom Performing Funds - The bottom 10 funds with the lowest net value growth include: 1. Guotai Innovation Medical Mixed Initiation C Fund (1.1799) 2. Guotai Innovation Medical Mixed Initiation A Fund (1.1901) 3. Wanjia Pharmaceutical Quantitative Stock Selection Mixed Initiation C Fund (1.2070) 4. Wanjia Pharmaceutical Quantitative Stock Selection Mixed Initiation A Fund (1.2165) 5. Morgan Stanley Youyue Anhe Mixed C Fund (0.6632) 6. Morgan Stanley Youyue Anhe Mixed A Fund (0.6727) 7. Hongde Medical Innovation Mixed Initiation A Fund (1.0426) 8. Hongde Medical Innovation Mixed Initiation C Fund (1.0274) 9. Guotai Growth Enterprise Board Medical Health ETF (1.2310) 10. Tianhong Medical Innovation A Fund (1.0690) [4][6]. Group 3: Market Overview - The Shanghai Composite Index showed a slight upward trend, with a trading volume of 1.75 trillion, and the number of advancing stocks was 3,357 compared to 1,817 declining stocks [6]. - Leading sectors included shipbuilding and general machinery, both rising over 3%, while the tourism sector experienced declines [6].

Group 1 - The chemical pharmaceutical sector increased by 0.48% on August 4, with Hai Chen Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] - Hai Chen Pharmaceutical's stock price rose by 20.01% to 41.27, with a trading volume of 285,300 shares and a transaction value of 1.101 billion [1] Group 2 - The top gainers in the chemical pharmaceutical sector included Han Yu Pharmaceutical, which rose by 19.98% to 24.32, and Guangsheng Tang, which increased by 18.18% to 120.90 [1] - The sector saw a net inflow of 97.0043 million in main funds, while retail investors contributed a net inflow of 1.279 billion [2] - The main funds showed significant net outflows in several companies, including Hai Chen Pharmaceutical, which had a net inflow of 182 million, but retail investors had a net outflow of 579.696 million [3]

Core Insights - The pharmaceutical industry in Taizhou has maintained a double-digit annual growth rate over the past decade and has ranked among the top ten in China's biopharmaceutical industrial park competitiveness for two consecutive years [7][8] - The "Shanghai R&D + Taizhou Manufacturing" model is being developed to create synergies between the two regions, leveraging Taizhou's manufacturing capabilities and Shanghai's research strengths [7][8] Industry Development - Taizhou has established itself as a hub for the biopharmaceutical industry, with over 1,300 health enterprises, including 14 multinational companies [11] - The city has seen significant achievements, including eight local incubated companies going public and several others in the IPO pipeline [8][9] - The local government has implemented supportive policies to foster the growth of the pharmaceutical sector, including the establishment of a comprehensive drug supervision service complex [9][12] Financial Support - Financial institutions are actively investing in Taizhou's pharmaceutical sector, creating a "capital rainforest" ecosystem that provides targeted financial support [8][16] - Various financial models, such as "incubation + angel investment" and "venture capital + insurance," have been developed to support the industry [8][16] - Investment firms express confidence in Taizhou as a favorable investment destination, with many seeking to replicate successful investment models from other regions [16][18] Innovation and Collaboration - Taizhou is focusing on future industries such as synthetic biology and gene therapy, aiming to create a highland for the health industry [9][10] - Companies are exploring collaborative opportunities with Taizhou, leveraging its existing development foundation to enhance innovation and growth [13][14] - The city is seen as a key area for Shanghai's pharmaceutical companies to find acquisition targets and optimize their industrial layout [12][14] Government and Policy Support - Local government support is crucial for the development of the pharmaceutical industry, with calls for enhanced policies to facilitate innovation and market expansion [14][19] - The establishment of platforms for international cooperation and clinical trials is expected to help local companies expand into global markets [14][19] - The government is encouraged to continue fostering a supportive environment for research and development, particularly in the context of innovative drug production and commercialization [14][19]